Combating immunity

Combating immunity to AAV Ensuring as many patients as possible can benefit from gene therapy The Duchenne Research Fund has awarded a grant to Dr Barry Byrne and Dr Manuela Corti’s team at the University of Florida, whose vital work focuses on overcoming...

Non-viral delivery

Non-viral delivery for gene therapy A next generation gene therapy delivery approach The Duchenne Research Fund committed £320,000 to accelerate research into alternative ways to deliver gene therapy to Duchenne patients, with the aim of increasing the number of...

Gene therapy for Becker

Gene therapy for Becker A microdystrophin gene therapy approach for Becker muscular dystrophy The Duchenne Research Fund has awarded a grant to the team of Professor Thomas Voit (pictured) at the Great Ormond Street Biomedical Research Centre at UCL to develop a...

Solid Biosciences’ gene therapy

Solid GT Ground-breaking gene therapy platform for Duchenne (IGNITE DMD Clinical Trial) In May 2026, Solid Biosciences announced that the first participant had been dosed in the Phase III clinical study of its next-generation gene therapy, SGT-003. The patient was...